Oculis' OCS-01 Fails Phase 3 DIAMOND Trials for Diabetic Macular Edema; FDA Filing Abandoned
OCS is trading near its 52-week low of $16 (11% below the low) on elevated volume (6.7× avg).
Summary
Oculis' OCS-01 drug failed to meet its primary efficacy endpoint in Phase 3 trials for diabetic macular edema, leading the company to abandon FDA filing plans for this indication and re-prioritize its pipeline.
Key Events · Product Development and Regulatory · OCS
-
OCS-01 Phase 3 Failure
The OCS-01 eye drops did not meet the primary endpoint of improved best corrected visual acuity (BCVA) in two Phase 3 DIAMOND trials for diabetic macular edema (DME).
-
FDA Filing Abandoned
Oculis will not pursue an FDA regulatory filing for OCS-01 in DME following the trial results.
-
Pipeline Re-prioritization
The company will shift its development focus and financial resources to its Privosegtor program for optic neuropathies and Licaminlimab for dry eye disease.
-
Strong Cash Runway
Oculis reported a strong cash position of $278 million as of March 31, 2026, providing a cash runway into the second half of 2029.
Analysis · OCS · Life Sciences
Oculis announced that its OCS-01 eye drops failed to meet the primary endpoint in two Phase 3 trials for diabetic macular edema (DME). This critical setback means the company will not pursue FDA approval for OCS-01 in this indication, leading to a significant re-evaluation of its pipeline and future revenue potential. The company will now pivot its focus to other late-stage programs, Privosegtor for optic neuropathies and Licaminlimab for dry eye disease, while leveraging its strong cash position.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OCS was trading at $14.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $16.00 to $34.48. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.